Baxter raises guidance but the margin ramp remains steep
- Management raised full-year organic sales guidance after a broad second-quarter beat.
- The company identified corrections for the Novum LVP pump and began verification testing.
- Management still needs a steep second-half operating margin lift to hit 2026 goals.
- High-margin injectables are supply constrained, with limited supply expected into 2027.
- U.S. hospital capital spending has not slowed, which supports beds, monitors, and surgical systems.
A narrower Baxter must prove itself
Baxter has finished its big portfolio reset. It sold BioPharma Solutions in 2023 and Kidney Care in January 2025. The company recently reorganized its remaining pieces, moving Pharmaceuticals into the Medical Products and Therapies segment to simplify operations.
The bull case sees momentum building. Second-quarter 2026 results prompted management to raise full-year organic sales growth guidance to 2 to 3 percent. Crucially, the company has identified fixes for its stalled Novum LVP pump and started verification testing. If cost cuts offset stranded expenses from past sales, debt will fall toward management's target of 3x net leverage by the end of 2026.
The bear case remains focused on execution. The Novum LVP hold is still assumed to last all of 2026. A contract manufacturer problem is expected to limit supply of high-margin injectables into 2027. To meet its full-year plan, Baxter is relying heavily on margin expansion in the second half of 2026. That is a tall order when lower-margin drug compounding is outgrowing higher-margin injectables.
Finn's view is cautious but improving. Baxter has essential products and a cleaner portfolio. The second-quarter update provided the first real signs of progress, but the next year is mostly about proving the cost savings are permanent.
Hospitals buy the essentials
Baxter makes money by selling needed products to hospitals and other care providers. These include IV solutions, pumps, administration sets, surgical sealants, smart beds, patient monitors, respiratory tools, injectable drugs, inhaled anesthesia, and drug compounding services.
Many of these products are repeat-use hospital supplies. That can make demand steadier than demand for one-time devices. However, hospital contracts can also make it hard to pass through higher labor, shipping, and manufacturing costs quickly.
The company is smaller after divestitures. Baxter used sale proceeds to repay large amounts of debt, including $3.81 billion of legacy indebtedness in 2025. Management continues to target lower leverage to give the company more financial flexibility.
The break point is execution. A smaller Baxter must cover stranded costs, fix the Novum LVP issue, clear drug supply problems, and keep hospitals buying its capital equipment.
Products that touch the hospital floor
IV solutions and administration sets
These are core hospital consumables inside the new Infusion Therapies and Platforms division. Demand is steady, and sales grew by double digits in the second quarter of 2026.
Infusion pumps, including Novum IQ
Pumps can tie Baxter deeper into hospital workflows. The Novum LVP hold blocks meaningful sales for now, but verification testing for corrections has started.
Advanced Surgery products
This line includes hemostats, sealants, and adhesion prevention products. Advanced Surgery sales rose 12% in the second quarter of 2026.
Connected care, beds, and monitoring
Healthcare Systems and Technologies sells smart beds, patient monitoring, diagnostic tools, and care communications. Management noted strong patient support systems volumes in 2026.
Front Line Care
This includes respiratory health and related care tools. The segment saw a return to growth in the second quarter of 2026.
Injectables and inhaled anesthesia
These are important profit drivers now managed within Medical Products and Therapies. Sales have fallen as supply constraints hit select higher-margin products.
Drug compounding
Drug compounding grew fast in the first half of 2026. The catch is mix, since this growth does not fully replace lost high-margin injectable sales.
Two reportable engines
Mix is estimated based on the Q2 2026 consolidation of the Pharmaceuticals segment into Medical Products and Therapies, applied to historical revenue proportions.
What could break the plan
Novum LVP testing fails or drags on
High impact · Medium oddsBaxter expects no meaningful Novum LVP sales while the ship and installation hold remains in effect. The company has started verification testing. If the corrections fail or the FDA requires a lengthy refile, the company could permanently lose hospital customers to rivals.
Injectables shortage drags margins into 2027
High impact · Medium oddsA contract manufacturer problem is limiting supply of higher-margin injectable products. Management said limited supply is expected into 2027. Drug Compounding is growing, but it represents a weaker profit mix if it replaces higher-margin injectables.
The second-half margin ramp is missed
High impact · Medium oddsBaxter needs steep operating margin expansion in the second half of 2026 to meet its plan. That relies on Baxter GPS savings, seasonal volume, and tight cost control. If costs remain high, the ramp may be too steep to climb.
Debt limits the recovery
Medium impact · Medium oddsBaxter has reduced debt, but leverage still matters. S&P and Moody's moved the company's credit outlook from Stable to Negative in early 2026. A missed margin ramp could make the year-end 2026 net leverage goal harder to reach.
Hospital capital spending slows
Medium impact · Medium oddsHealthcare Systems and Technologies depends partly on hospitals buying beds, monitors, and surgical systems. Management said it has not seen a U.S. slowdown, but tariffs, inflation, or budget pressure could change that.
In one breath
What does Baxter do after selling Kidney Care?
Baxter now focuses on two continuing segments: Medical Products and Therapies, and Healthcare Systems and Technologies. It sells hospital supplies, connected care systems, surgical products, and specialty drugs.
Why does the Novum LVP pump matter for Baxter stock?
Novum LVP is part of Baxter's infusion pump business. The company has stopped most shipments while corrections are handled, which blocks meaningful revenue. The company recently started verification testing on a fix.
Is Baxter a growth stock or a turnaround?
Right now it is a turnaround. The portfolio is cleaner, but investors need proof that cost cuts, product fixes, and debt reduction can rebuild earnings power.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 30, 2026
- Score data
- September 6, 2026
- Reviewed by
- Shivam Bharuka
Comparable Medical Instruments & Supplies companies
Companies near Baxter International Inc. in Finn's Medical Instruments & Supplies industry ranking.
